INTRODUCTION {#s1}
============

Thyroid cancer is one of the most common cancers in the endocrine system, and the incidence of thyroid cancer is about 1%, and it is also the main cause of death in the endocrine system \[[@R1]\]. There are around 44670 new cases and 1690 deaths of thyroid cancer every year \[[@R2]\]. In the past years, the average annual percentage for thyroid cancer increased 5.3% per year \[[@R3]\]. Currently, the diagnostic methods of thyroid cancer mainly include ultrasound, CT and fine-needle aspiration cytology. In a certain extent, it can improve the accuracy of diagnosis of thyroid cancer. However, surveillance, early and precision diagnosis as well as treatment are still the main problem \[[@R4]\]. Currently there are ThyroSeqV2 next generation sequencing assay to improve the diagnosis of benign and malignant thyroid cancer method \[[@R5]\], which is high accuracy but high cost, and can not be popularized. So new methods is necessary in the diagnosis of thyroid cancer.

Thyroid stimulating hormone receptor (TSHR) is a specific protein of thyroid cells, which is found on the membrane of thyroid gland cells. It plays an important role in the development of thyroid function and thyroid disease. Because TSHR-mRNA is over-expressed in thyroid cancer cells, the measurement of TSHR-mRNA in the circulation is very valuable for the diagnosis of thyroid cancer \[[@R4]\]. In recent years, there have been many reports of TSHR-mRNA in the diagnosis of thyroid cancer. However, a system evaluation of TSHR-mRNA as a diagnostic biomarker for thyroid cancer is deficient, so we made this first diagnosis meta-analysis of TSHR-mRNA on thyroid cancer.

RESULTS {#s2}
=======

Characteristics and quality of the included studies {#s2_1}
---------------------------------------------------

The literature search identified 67 relevant articles. Titles and abstracts were preliminarily reviewed and a total of 55 articles were excluded for various reasons (including literature type is review, case reports and letter, or studies do not solely focus on TSHR-mRNA and/or not specifically pertain to thyroid cancer). The article selection process is summarized in Figure [1](#F1){ref-type="fig"}. Finally, nine publications were included for this meta-analysis \[[@R6]--[@R14]\].

![Flow chart of selection process for eligible studies](oncotarget-08-6623-g001){#F1}

The nine included studies were published between 2005 and 2015, of which 1027 patients were involved. 4 out of 9 articles were published in China. RT-PCR was applied for TSHR-mRNA detection, with histopathological examination as the gold standard for thyroid cancer diagnosis. The detailed characteristics of these studies are listed in Table [1](#T1){ref-type="table"}.

###### Main characters of the studies included in the meta-analysis

  Studies      year   country   patients   Reference standard              Patient type                                                                                        cut-off(ng/ug)   TP    FP   FN   TN
  ------------ ------ --------- ---------- ------------------------------- --------------------------------------------------------------------------------------------------- ---------------- ----- ---- ---- -----
  Wagner, K    2005   USA       46         FNA and/OR Surgical pathology   All TC[^a^](#tfn_001){ref-type="table-fn"}; FNA indeterminate[^b^](#tfn_002){ref-type="table-fn"}   1.02             16    5    6    19
  Chia, S.Y    2007   USA       131        FNA and/OR Surgical pathology   All TC                                                                                              1.02             56    15   21   39
  Milas, M     2010   USA       368        Surgical pathology              All TC                                                                                              1                124   29   78   137
  Salwa, H     2011   Egypt     40         FNA                             All TC; FNA indeterminate                                                                           1.02             20    2    4    14
  Gutnick, J   2012   USA       39         FNA and/OR Surgical pathology   All TC                                                                                              1                8     5    3    23
  Jiang, LH    2012   China     126        Surgical pathology              All TC                                                                                              1.02             56    1    0    69
  Liu, X W     2012   China     130        FNA and/OR Surgical pathology   All TC                                                                                              1.02             26    11   24   69
  Ren, T T     2013   China     67         FNA and/OR Surgical pathology   All TC                                                                                              1.02             31    16   3    17
  Jiang, W     2015   China     80         Surgical pathology              All TC                                                                                              1.5              45    6    7    22

TP (true-positive), FP (false-positive), FN (false-negative), TN (true-negative), c-c(case-control), cut-off(Positive boundary value).

: All thyroid cancer.

: FNA diagnosis of indeterminate.

The methodological quality of the studies according to the QUADAS-2 tool is summarized in Figure [2](#F2){ref-type="fig"}, and the methodological quality was generally better.

![Quality assessments of included studies by using the QUADAS-2 tool\
Methodological quality was generally better. The risk of bias in terms of flow and timing and patient selection and was met by less than 30% of the studies. Only three studies unfulfilled all criteria.](oncotarget-08-6623-g002){#F2}

Overall analysis {#s2_2}
----------------

There was heterogeneity presented in this meta-analysis, as revealed by the results (Q = 21.979, p =0.000, I^2^=91). Thus, a random effects model was used for the further analysis. As shown in Figure [3](#F3){ref-type="fig"}, the sensitivity and specificity for the pooled data were 0.72 (0.68 to 0.76) and 0.82 (0.78 to 0.85), respectively. The AUC was 0.84 (Figure [4](#F4){ref-type="fig"}), and the DOR was 12.93 (6.89 to 24.24). The results corresponded to a PLR (Positive Likelihood Ratio) of 3.71 (2.51, 5.50) and an NLR (Negative Likelihood Ratio) of 0.31 (0.21, 0.46). High heterogeneity was demonstrated in the sensitivity (I^2^= 88.9%) and specificity (I^2^ = 80.5%).

![Forest plots of the sensitivity and specificity for THSR-mRNA in the diagnosis of thyroid cancer\
The point estimates of sensitivity and specificity for each study are shown as solid circles and size of each solid circle indicates the sample size of each study. Error bars are 95% confidence intervals.](oncotarget-08-6623-g003){#F3}

![Summary receive operating characteristic (SROC) curve for THSR-mRNA in the diagnosis of thyroid cancer\
Solid circles represent each study included in the meta-analysis. The size of each solid circle indicates the size of each study. The regression SROC curve summarizes the overall diagnostic accuracy.](oncotarget-08-6623-g004){#F4}

Threshold effect and publication bias {#s2_3}
-------------------------------------

To retrospect the cause of high heterogeneity, the threshold was firstly analyzed. There was no threshold effect presenting in this meta-analysis, which was supported by the spearman correlation coefficient \[[@R15]\] value of 0.100 (p = 0.862; p \> 0.05).

Besides threshold effect, heterogeneity can also be contributed by socio-demographic characteristics and geographical location \[[@R16]\]. Then, geographical location and patient characters were analyzed with a meta-regression. No significant heterogeneity was demonstrated in terms of geographical location (coefficient = 0.220, p = 0.283) and patient characters (coefficient = 0.000, p = 0.988). Therefore, other factors might contribute to the observed high heterogeneity.

Furthermore, the potential publication bias was evaluated by Deeks' funnel plots. The p-value of 0.73 suggested there is no publication bias (Figure [5](#F5){ref-type="fig"}).

![Deek\'s plots for the assessment of publication bias\
The funnel graph plots the log of the diagnostic odds ratio (DOR) against the standard error of the log of the DOR (an indicator of sample size). Solid circles represent each study in the meta-analysis. The line indicates the regression line.](oncotarget-08-6623-g005){#F5}

Sensitivity analysis {#s2_4}
--------------------

The sensitivity value range is 0.69 (0.65-0.73) to 0.79 (0.74-0.83), specificity value range of 0.79 (0.75-0.83) to 0.84 (0.81-0.87) the AUC of the range is 0.829 to 0.884. Sensitivity analysis showed that the results were stable and there was no bias.

DISCUSSION {#s3}
==========

The preoperative evaluation of thyroid nodules currently depends on fine needle aspiration (FNA) biopsy. However, FNA suffer inherent limitations. Its inadequate sampling may occasionally led to cancer cell missing and 15--30% of cases are indeterminate \[[@R17]--[@R19]\]. In addition, FNA is virtually impossible to differentiate follicular cancers (FC) from benign follicular adenomas (FA), and thus molecular markers is urgently necessary for this purpose \[[@R20]--[@R24]\].

Thyroid and thyroid cancer cells specifically express TSHR-mRNA, increasing evidences have demonstrated that circulating TSHR-mRNA is involved in cancer diagnosis and prognosis. The latest article shows that TSHR-mRNA is a molecular marker of thyroid cancer cells circulating \[[@R25]\]. However, there is no systematic evaluation for these studies.

In this work, we conducted the first diagnostic meta-analysis to draw a system evaluation for TSHR-mRNA on the diagnosis of thyroid cancer. An AUC of 0.8427 showed that circulating TSHR-mRNA may be a promising biomarker to discriminate thyroid cancer patients from benign thyroid nodules individuals, with a summary sensitivity of 72% and specificity of 83%. As a potential diagnostic biomarker for thyroid cancer, serum or plasma TSHR-mRNA is characterized by minimal invasion and convenience compared with FNA based histopathological examination. In addition, TSHR-mRNA could serve to monitor the disease recurrence after surgery \[[@R26]\].

However, as a novel biomarker, circulating TSHR-mRNA for thyroid cancer diagnosis have been conducted in limited studies \[[@R27]\]. Therefore, no large number of patient can be included in this meta-analysis. The finding in this work need validation in large-scale clinical studies. Further more, we supposed TSHR-mRNA combined with FNA should have better performance than anyone alone \[[@R13], [@R28]--[@R30]\]. Unfortunately, these studies were too few for further analysis.

Overall, this meta-analysis indicates that circulating TSHR-mRNA is potential to be a biomarker for early-stage thyroid cancer diagnosis. However, future clinical studies are necessary to validate this finding.

MATERIALS AND METHODS {#s4}
=====================

Search strategy and study selection {#s4_1}
-----------------------------------

The method of literature search is the same as we have just published \[[@R31], [@R32]\]. With the Medical Subject Headings or text words 'TSHR mRNA', combined with 'Thyroid cancer' or 'Thyroid neoplasm', a computerized search were conducted for studies that were published between 1972 and February 2015 in the databases of PUBMED, MEDLINE and EMBASE and Chinese National Knowledge Infrastructure. Moreover, the reference lists of retrieved articles were manually searched for additional relevant studies. No language restrictions were applied.

Studies that is inability to obtain individual data, review articles, case reports, using the same sample, absence of case or control groups, using specimens other than human, using specimens other than those obtained exclusively from the blood (for example, thyroid gland tissue and derivatives) were excluded.

Data extraction and quality assessment {#s4_2}
--------------------------------------

The data were independently collected from the included studies and reached a consensus on all items by two researchers. Any disagreements would be resolved by discussion with a third author for a final consensus. The following information was collected: reference, number of patients, technique employed, histological types of neoplasias. In addition, the following data were extracted: first author\'s name, publication year, country, cutoff value, patients size, TP (true-positive), FP (false-positive), FN (false-negative) and TN (true-negative).

Methodological quality of the primary studies was assessed by the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) checklist \[[@R33]\].

Meta analysis {#s4_3}
-------------

Statistical analysis was conducted with Meta-DiSc 1.4 and Stata 12.0 \[[@R15]\]. In the analysis, benign thyroid cancer served as negative control. P \< 0.05 was set as statistical significance. A value of I^2^ \> 50% and/or a p \< 0.05 indicated the between-study heterogeneity \[[@R34]\]. When heterogeneity was presented in the study, a random effects model was applied to sensitivity, specificity, likelihood ratio, and diagnostic odds ratio. The threshold effect was investigated based on the spearman correlation coefficient. A summary receiver operating characteristic curve (SROC) was used for the overall evaluation of diagnostic performance. Publication bias was assessed using Deeks' funnel plot analysis \[[@R35]\].
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